I value being part of the largest and fastest growing user community of its kind in the world
As well as contributing to the longevity and well-being of every European citizen, the research-based pharmaceutical industry is a key asset of the European economy representing about 19% of global business R&D investments and approximately 3.5% of the total EU manufactured exports. The research-based pharmaceutical industry employs approximately 643,000 people of which 107,000 work in R&D in Europe.
Pharmaceutical R&D productivity and investment in Europe continues to grow. However over the past 2 decades this growth has been sluggish in comparison to that experienced by the United States and emerging economies such as China and India.
Strict industry regulation, rising R&D costs, the rise in parallel trading and drug counterfeiting and societal attitudes to pharmaceutical innovation have contributed to the steady transfer of R&D from Europe to the US and Asia.
In response, the European Commission and the European Federation of Pharmaceutical Industries and Associations (EFPIA) have introduced the Innovative Medicines Initiative (IMI), a unique pan-European public and private sector collaboration for boosting biomedical research in Europe.
The IMI initiative aims to accelerate the discovery and development of better medicines by removing bottlenecks in the drug development process. It focuses on creating better methods and tools that improve and enhance the drug development process, rather than on developing specific, new medicines.
A key focus of the IMI is on removing the bottlenecks in pre-clinical R&D and this is where Instem plays a critical role, providing clients with world-leading software solutions that increase productivity and streamline processes.
Instem’s commitment to the European market is well established. We have been a dominant provider of pre-clinical IT solutions to the European life-sciences market for over 30 years, providing traditional on-site or Software-as-a-Service (SaaS) solutions to our clients.
Instem’s UK headquarters house Executive Management , Solution Development, Client Services, Sales & Marketing and Customer Support functions, and it is from its UK base that Instem support its many clients across sites in the UK, Sweden, Germany, France, Italy, Holland, Hungary, Denmark and Norway.
Instem continues to maintain a leadership position in Europe and its user base continues to grow. Instem has a commanding share of the global preclinical IT market and invests more in product development annually than any other vendor in its market.